Hodgkin's disease and the Epstein-Barr virus

Journal of Clinical Pathology - Molecular Pathology

Volumn 53, Issue 5, 2000, Pages 262-269

  Flavell, K J ^b   Murray, P G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Epstein Barr virus; Hodgkin's disease; Hodgkin Reed Sternberg cells

Indexed keywords

CANCER CELL; EPSTEIN BARR VIRUS; GENE EXPRESSION; HODGKIN DISEASE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; VIRUS CARCINOGENESIS; VIRUS GENOME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; GENOME, VIRAL; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IN SITU HYBRIDIZATION; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REED-STERNBERG CELLS; SEX FACTORS; SOCIOECONOMIC FACTORS; TUMOR VIRUS INFECTIONS;

EID: 0033781798     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.53.5.262     Document Type: Review

References (116)

1. 1 Rosenthal SR. Significance of tissue lymphocytes in the prognosis of lymphogranulomatosis. Arch Pathol 1936;21:628-31.
2. 2 Jackson H, Parker F. Hodgkin's disease: II. Pathology. N Engl J Med 1944;231:35-44.
3. 3 Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966;26:1063-81.
4. 4 Lukes RJ, Carver LF, Hall TC, et al. Report of the nomenclature committee in symposium: obstacles to the control of Hodgkin's disease. Cancer Res 1966;26:1311.
5. 5 Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994; 84:1361-92.
6. 6 Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I Biopsy material. Leuk Lymphoma 1992;8:283-313.
7. 7 Pinto A, Gattei V, Zagonel V, et al. Hodgkin's disease: a disorder of dysregulated cellular cross-talk. Biotherapy 1998; 10:309-20.
8. 8 Linden MD, Fishleder AJ, Katzin WE, et al. Absence of B-cell or T-cell clonal expansion in nodular, lymphocyte predominant Hodgkin's disease. Hum Pathol 1988;19:591-94.
9. 9 Stoler MH, Nichols GE, Symbula M, et al. Lymphocyte predominance Hodgkin's disease - evidence for a kappa light chain-restricted monotypic B-cell neoplasm. Am J Pathol 1995;146:812-18.
10. 10 Nicholas DS, Harris S, Wright DH. Lymphocyte predominance Hodgkin's disease - an immunohistochemical study. Histopathology 1990;16:157-65.
11. 11 Kadin M, Stites D, Levy R, et al. Exogenous immunoglobulin and the macrophage origin of the Reed-Sternberg cells in Hodgkin's disease. N Engl J Med 1978;299:1208-14.
12. 12 Curran RL, Jones EL. Hodgkin's disease: an immunohistochemical and histological study. J Pathol 1978;125:39-51.
13. 13 Stein H, Uchanska-Ziegler B, Gerdes J, et al. Hodgkin and Sternberg-Reed cells contain antigens specific to late granulopoiesis. Int J Cancer 1982;29:283-90.
14. 14 Jaffe ES. The elusive Reed-Sternberg cell. N Engl J Med 1989;320:529-31.
15. 15 Diehl V, von Kalle C, Fonatsch C, et al. The cell of origin in Hodgkin's disease. Semin Oncol 1990;17:660-72.
16. 16 Oudejans JJ, Kummer JA, Jiwa M, et al. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 1996;148:233-40.
17. 17 Stein H, Hummel M, Marafioti T, et al. Molecular biology of Hodgkin's disease. Cancer Surv 1997;30:107-23.
18. 18 Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-13.
19. 19 Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994;91:10962-6.
20. 20 Delabie J, Tierens A, Wu G, et al. Lymphocyte predominance Hodgkin's disease: lineage and clonality determination using a single-cell assay. Blood 1994;84:3291-8.
21. 21 Hummel M, Ziemann K, Lammert H, et al. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med 1995;333:901-6.
22. 22 Delabie J, Tierens A, Gavriil T, et al. Phenotype, genotype and clonality of Reed-Sternberg cells in nodular sclerosis Hodgkin's disease: results of a single-cell study. Br J Haematol 1996;94:198-205.
23. H genes in different biopsies in relapsed Hodgkin's disease. Blood 1998;92: 2899-907.
24. 24 Kanzler H, Kuppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184: 1495-505.
25. 25 Marafioti T, Hummel M, Foss H-D, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal centre B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-50.
26. 26 Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997;337:453-8.
27. 27 Müschen M, Rajewsky K, Bräuninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 2000;191:387-94.
28. 28 Cossman J, Annunziata CM, Barash S, et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 1999;94:411-16.
29. 29 Kapp U, Yeh W-C, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999;189:1939-46.
30. 30 MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res 1996;26:1189-200.
31. 31 Devore JW, Doan CA. Studies in Hodgkin's syndrome. XII. Hereditary and epidemiologic aspects. Ann Intern Med 1957;47:300-16.
32. 32 Razis DV, Diamond HD, Craver LF. Familial Hodgkin's disease: its significance and implications. Ann Intern Med 1959;51:933-71.
33. 33 Cridland MD. Seasonal incidence of clinical onset of Hodgkin's disease. BMJ 1961;2:621-3.
34. 34 Fraumeni JF, Jr, Li FP. Hodgkin's disease in childhood: an epidemiologic study. J Natl Cancer Inst 1969;42:681-91.
35. 35 Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. Int J Cancer 1971;8:192-201.
36. 36 Gutensohn N, Cole P. Epidemiology of Hodgkin's disease. Semin Oncol 1980;7:92-102.
37. 37 Gutensohn N, Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med 1981;304:135-40.
38. 38 Gutensohn NM. Social class and age at diagnosis of Hodgkin's disease; new epidemiologic evidence on the "two-disease" hypothesis. Cancer Treat Rep 1982;66:689-95.
39. 39 Levine PH, Ablashi DV, Berard CW, et al. Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer 1971;27:416-21.
40. 40 Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus: altered antibody pattern before diagnosis. N Engl J Med 1989;320:689-95.
41. 41 Clark DA, Alexander FE, McKinney PA, et al. The sero-epidemiology of human herpes virus-6 (HHV-6) from a Yorkshire case-control study of leukaemia and lymphoma. Int J Cancer 1990;45:829-33.
42. 42 Alexander FE, Daniel CP, Armstrong AA, et al. Case clustering, Epstein-Barr virus Reed-Sternberg cell status and herpes virus serology in Hodgkin's disease: results of a case control study. Eur J Cancer 1995;31A:1479-86.
43. 43 Levine PH, Pallesen G, Ebbesen P, et al. Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. Int J Cancer 1994;59:48-50.
44. 44 Evans AS, Gutensohn NM. A population-based case control study of EBV and other viral antibodies among persons with Hodgkin's disease and their siblings. Int J Cancer 1984;34:149-57.
45. 45 Armstrong JA, Evans AS, Rao N, et al. Viral infection in renal transplant recipients. Infect Immun 1976;14:970-5.
46. 46 Weiss LM, Strickler JG, Warnke RA, et al. Epstein-Barr viral DNA in tissues of Hodgkin's disease. Am J Pathol 1987;129:86-91.
47. 47 Anagnostopoulos I, Herbst H, Niedobitek G, et al. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989;74:810-16.
48. 48 Weiss LM, Movahed LA, Warnke RA, et al. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-6.
49. 49 Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 1990;46:801-4.
50. 50 Bonnet M, Guinebretiere J-M, Kremmer E, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999;91:1376-81.
51. 51 Sugawara Y, Mizugaki Y, Uchida T, et al. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology 1999;256: 196-202.
52. 52 Herbst H, Niedobitek G. Epstein-Barr virus and Hodgkin's disease. Int J Clin Lab Res 1993;23:13-16.
53. 53 Coates PJ, Slavin G, D'Ardenne AJ. Persistence of Epstein-Barr virus in Reed-Sternberg cells throughout the course of Hodgkin's disease. J Pathol 1991;164:291-7.
54. 54 Jarrett AF, Armstrong AA, Alexander E. Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 1996;7(suppl 4):S5-10.
55. 55 Razzouk BI, Srinivas S, Sample CE, et al. Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis 1996;173:529-35.
56. 56 Staratschek-Jox A, Kotkowski S, Belge G, et al. Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells: no evidence for the persistence of integrated viral fragments in latent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease. Am J Pathol 2000;156:209-16.
57. 57 Weiss LM, Chen Y-Y, Liu X-F, et al. Epstein-Barr virus and Hodgkin's disease: a correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991;139: 1259-65.
58. 58 Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood 1992;80:484-91.
59. 59 Hummel M, Anagnostopoulos I, Dallenbach F, et al. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of gene products. Br J Haematol 1992;82:689-94.
60. 60 Zhou X-G, Hamilton-Dutoit SJ, Yan Q-H, et al. The association between Epstein-Barr virus and Chinese Hodgkin's disease. Int J Cancer 1993;55:359-63.
61. 61 Chang KL, Albujar PF, Chen Y-Y, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993;81:496-501.
62. 62 Leoncini L, Spina D, Nyong'o A, et al. Neoplastic cells of Hodgkin's disease show differences in EBV expression between Kenya and Italy. Int J Cancer 1996;65:781-4.
63. 63 Weinreb M, Day PJR, Niggli F, et al. The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 1996;87:3828-36.
64. 64 Weinreb M, Day PJR, Niggli F, et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child 1996;74:27-31.
65. 65 Uccini S, Monardo F, Stoppacciaro A, et al. High frequency of Epstein-Barr virus-genome detection in Hodgkin's disease of HIV-positive patients. Int J Cancer 1990;46:581-5.
66. 66 Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991;337:320-2.
67. 67 Murray PG, Young LS, Rowe M, et al. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol 1992;166:1-5.
68. 68 Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997;70:375-82.
69. 69 Jarrett RF, Gallagher A, Jones DB, et al. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. J Clin Pathol 1991;44:844-8.
70. 70 Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia 1998;12:1272-6.
71. 71 Flavell KJ, Biddulph JP, Constandinou CM, et al. Variation in the frequency of Epstein-Barr virus-associated Hodgkin's disease with age. Leukemia 2000;14:748-53.
72. 72 Armstrong AA, Shield L, Gallagher A, et al. Lack of involvement of known oncogenic DNA viruses in Epstein-Barr virus-negative Hodgkin's disease. Br J Cancer 1998;77: 1045-7.
73. 73 Flavell K, Constandinou C, Lowe D, et al. Effect of material deprivation on Epstein-Barr virus infection in Hodgkin's disease in the West Midlands. Br J Cancer 1999;80:604-8.
74. 74 Grässer FA, Murray PG, Kremmer E, et al. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA 1): immunohistologic detection of EBNA 1 in the malignant cells of Hodgkin's disease. Blood 1994;84:3792-8.
75. 75 Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993;177: 339-49.
76. 76 Niedobitek G, Kremmer E, Herbst H, et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 1997;90:1664-72.
77. 77 Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-18.
78. 78 Nakagomi H, Dolcetti R, Bejarano MT, et al. The Epstein-Barr-virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt-lymphoma lines. Int J Cancer 1994;57:240-4.
79. 79 Kim SH, Shin YK, Lee I-S, et al. Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood 2000;95:294-300.
80. 80 Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
81. 81 Laherty CD, Hu HM, Opipari AW, et al. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992;267:24157-60.
82. 82 Wang S, Rowe M, Lundgren E. Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996;56:4610-13.
83. 83 Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell-specific response that is delayed relative to NF-kappa B activation and to induction of cell surface markers. J Virol 1994;68:5602-12.
84. 84 Herrero JA, Mathew P, Paya CV. LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. J Virol 1995;69:2168-74.
85. 85 Huen DS, Henderson SA, Groom-Carter D, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
86. 86 Mitchell T, Sugden B. Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 1995;69:2968-76.
87. 87 Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99.
88. 88 Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1995;87:4340-7.
89. 89 Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-Re1A activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-9.
90. 90 Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the IκBa gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000;191:395-401.
91. 91 Khan G, Gupta RK, Coates PJ, et al. Epstein-Barr virus infection and bcl-2 proto-oncogene expression: separate events in the pathogenesis of Hodgkin's disease? Am J Pathol 1993;143:1270-4.
92. 92 Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 1996;87:706-11.
93. 93 Herbst H, Foss HD, Samol J, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996;87:2918-29.
94. 94 Herbst H, Samol J, Foss HD, et al. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol 1997;182:299-306.
95. 95 Durkop H, Foss HD, Demel G, et al. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood 1999;93:617-23.
96. 96 Murray PG, Flavell JR, Lowe D, et al. Expression of the tumor necrosis factor receptor-associated factors-1 and -2 in Hodgkin's disease. J Pathol [In press.]
97. 97 Hu LF, Chen F, Zheng X, et al. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993;8: 1575-83.
98. 98 Knecht H, Bachmann E, Brousset P, et al. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993;82:2937-42.
99. 99 Sandvej K, Peh SC, Andresen BS, et al. Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: high frequency of a 30 bp deletion in Malaysian and Danish peripheral T cell lymphomas. Blood 1994;84:4053-60.
100. 100 Khanim F, Yao Q-Y, Niedobitek G, et al. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 1996;88:3491-501.
101. 101 Bellas C, Santon A, Manzanal A, et al. Pathological, immunological, and molecular features of Hodgkin's disease associated with HIV infection in comparison with ordinary Hodgkin's disease. Am J Surg Pathol 1996;20: 1520-4.
102. 102 Santon A, Martin C, Manzanal AI, et al. Paediatric Hodgkin's disease in Spain: association with Epstein-Barr virus strains carrying latent membrane protein-1 oncogene deletions and high frequency of dual infections. Br J Haematol 1998;103:129-36.
103. 103 Panousis CG, Rowe DT. Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase. J Virol 1997;71:4752-60.
104. 104 Brielmeier M, Mautner J, Laux G, et al. The latent membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell immortalization. J Gen Virol 1996;77:2807-18.
105. 105 Rickinson AB, Moss DJ, Allen DJ, et al. Reactivation of Epstein-Barr virus specific cytotoxic T cells by in vitro stimulation with the autologous lymphoblastoid cell line. Int J Cancer 27:593-601.
106. 106 Thorley-Lawson DA, Israelsohn ES. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein. Proc Natl Acad Sci U S A 1987;84:5384-8.
107. 107 Khanna R, Burrows SR, Nicholls J, et al. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998;28:451-8
108. 108 Lee SP, Constandinou CM, Thomas WA, et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 1998;92:1020-30.
109. 109 Dukers DF, Jaspars LH, Vos W, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J Pathol 2000;190:143-9.
110. 110 Frisan T, Sjoberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995;86:1493-501.
111. 111 Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 1996;87:3844-51.
112. 112 Murray PG, Constandinou CM, Crocker J, et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Immunity to EBV in healthy virus carriers. Blood 1998;92:2477-83.
113. 113 Sing AP, Ambinder RF, Hong DJ, et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997; 89:1978-86.
114. 114 Roskrow MA, Suzuki N, Gan Yj, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998;91:2925-34.
115. 115 Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997;90:2429-36.
116. 116 Murray PG, Billingham LJ, Hassan HT, et al. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 1998;94:442-7.